Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06393738
Status:
RECRUITING
Last Update Posted:
2024-05-01
First Post:
2024-04-25
Brief Title:
A Study of ARV-393 in RelapsedRefractory Non-Hodgkin Lymphoma
Sponsor:
Arvinas Inc
Organization:
Arvinas Inc
Study Overview
Official Title:
A Phase 1 First in Human Study of ARV-393 in Adult Participants With Advanced Non-Hodgkins Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced RelapsedRefractory non-Hodgkins lymphoma to determine if ARV-393 may be a possible treatment option
ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas which may prevent slow or stop tumor growth This is the first time ARV-393 will be used by people The investigational drug will be given as an oral tablet
ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas which may prevent slow or stop tumor growth This is the first time ARV-393 will be used by people The investigational drug will be given as an oral tablet
Detailed Description:
This is an open-label multicenter phase 1 dose escalation study to evaluate the safety tolerability and preliminary anti-tumor activity of ARV-393 as a single agent in adult patients with relapsedrefractory non-Hodgkin lymphoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None